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Abstract: Over the last 6 years, the treatment of metastatic renal cell carcinoma (mRCC) has undergone dramatic changes. A better 
understanding of the pathogenesis and tumor biology of sporadic renal cell carcinoma has led to the approval of 6 drug regimens: 
3 oral multi-targeted tyrosine-kinase inhibitors (sorafenib, sunitinib, and pazopanib), 2 inhibitors of the mammalian target of rapamycin 
(temsirolimus and everolimus), and 1 monoclonal antibody against the vascular endothelial growth factor (bevacizumab). Pazopanib, 
a multi-targeted tyrosine kinase inhibitor that targets VEGFR-1, -2, and-3; PDGFR-α and PDGFR-β, and c-Kit, was approved for the 
treatment of mRCC in October 2009, several years after the other drugs in its class. The efficacy and safety of pazopanib in Phase I, 
II, and III trials will be examined and its role in mRCC treatment will be described. Future studies that may clarify pazopanib’s role in 
mRCC will be discussed. Based on pazopanib’s demonstrated efficacy in treatment-naïve and cytokine-refractory patients, along with 
a seemingly favorable toxicity profile compared with other multi-targeted tyrosine-kinase inhibitors, pazopanib may have a unique 
niche in the armamentarium of treatment options for mRCC. Results from ongoing studies are awaited to confirm pazopanib’s favorable 
efficacy-toxicity ratio, especially in comparison with the previous first-line standard-of-care, sunitinib.
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Introduction
There  were  an  estimated  58,000  new  cases  and 
13,000 deaths of kidney cancer in the US in 2010.1 
For  localized  kidney  cancer,  nephrectomy  is  the 
mainstay of treatment; however, about 20%–30% of 
these patients will develop recurrence (ie, stage IV or 
metastatic disease).2 In addition, as many as   one-third 
of all patients present with metastatic disease at initial 
  diagnosis.3 About 90% of kidney   cancers are renal cell 
carcinomas (RCC), and up to 80% of these are of clear-
cell histology.4,5 Despite limited clinical efficacy and 
significant toxicity, cytokine therapies (interferon-α 
[IFN-α] and interleukin-2 [IL-2]) were the standard 
of  care  in  the  pre-targeted  therapy  era.6    However, 
understanding of the pathogenesis of sporadic (non-
inherited) clear cell RCC has led to advances in treat-
ment for advanced RCC and the advent of the targeted 
therapy era. Specifically, it is now understood that 
dysfunction of the von   Hippel-Lindau (VHL) tumor 
suppressor gene leads to intracellular accumulation 
of the hypoxia-inducible factor (HIF), which results 
in  secretion  of  factors  under  its  control:  vascular 
endothelial growth factor (VEGF), platelet derived 
growth factor (PDGF), and others.7 Efforts to target 
HIF-mediated pathways have proven successful thus 
far in therapy of advanced RCC, with the bulk cen-
tered around inhibition of the VEGF axis (“down-
stream” of HIF) and mammalian target of rapamycin 
axis (“upstream” of HIF).
Treatment options for advanced RCC have now 
dramatically  increased,  with  six  new  treatments 
approved in the United States since December 2005. 
Three  multi-targeted  tyrosine  kinase  inhibitors  of 
the  VEGF  receptor  and  PDGF  receptor  have  been 
approved:  sorafenib8  (Nexavar®,  Bayer;  December 
2005),    sunitinib9  (Sutent®,  Pfizer;  January  2006), 
and  pazopanib10  (Votrient®,  GlaxoSmithKline; 
  October 2009). Two agents that inhibit mTOR have 
been approved: temsirolimus11 (Torisel®, Pfizer; May 
2007) and everolimus12   (Afinitor®, Novartis; March 
2009).  Finally,  a  humanized  monoclonal  antibody 
against VEGF, bevacizumab13,14 (Avastin®,   Genentech; 
July  2009),  was  approved  in  combination  with 
interferon-α. While there are now multiple options 
from which patients with mRCC and their doctors may 
choose, there may be more than one reasonable choice 
in  a  particular  setting  and  little  evidence  to  guide 
amongst them. In these situations, when   head-to-head 
comparisons  of  efficacy  have  not  been  performed, 
clinical decisions may be made based on other fac-
tors,  like  toxicity  profiles,  route  of  administration, 
patient  comorbidities,  and  financial  considerations. 
For example, sunitinib has been the standard of care 
for  treatment-naïve  patients  with  good-intermediate 
risk clear cell RCC. Recently, bevacizumab + IFN-α 
and  pazopanib  have  provided  additional  options  in 
this setting. This article will review the evidence for 
pazopanib in various settings of treatment for patients 
with advanced RCC, develop evidence-based treat-
ment algorithms, and discuss trials that may assist in 
making treatment decisions.
Mechanism of Action, 
pharmacokinetics, and  
Metabolism Profile: Preclinical  
and early clinical Data
Pazopanib (Votrient®, GW786034; GlaxoSmithKline) 
is  an  oral  multi-targeted  tyrosine  kinase  inhibitor 
(TKI) of VEGFR-1, -2, and -3; PDGFR-α, PDGFR-β; 
and  c-kit.15,16  Pazopanib  is  an  indazolylpyrimidine 
5-[[4-{(2,  3-dimethyl-2H-indazol-6-yl)methylamino}-
2-pyrimidinyl]amino]-2-methylbenzenesulfonamide 
and was discovered during screening for compounds 
that  inhibit  the  vascular  endothelial  growth  factor 
receptor-2 (VEGFR-2).16,17 In vitro, the kinase selec-
tivity of pazopanib was evaluated in a panel of 242 
purified  human  kinases  and  cellular  potency  was 
examined using ligand-induced autophosphorylation 
assays.18 Pazopanib inhibited VEGFR-2, PDGF-β and 
c-kit at low nanomolar concentrations, as did sunitinib, 
whereas pazopanib did not significantly inhibit Flt-3 
like sunitinib. In in vivo studies in mice, pazopanib 
inhibited VEGF-induced VEGFR-2 phosphorylation, 
tumor  angiogenesis,  and  growth  of  various  xeno-
graft  tumor  types,  including  the  Caki-2  renal  cell 
carcinoma model.19 Pharmacokinetic and pharmacody-
namic studies showed that a pazopanib concentration 
of $40 µmol/L inhibited VEGFR-2 phosphorylation 
in mice, whereas below this concentration inhibition 
was minimal. These data differed from the IC50 of 
0.02 µmol/L based on VEGF-stimulated proliferation 
in in vitro models, which was attributed to significant 
protein  binding  of  pazopanib.19  Therefore,  a  target 
steady-state   concentration (Cmin) of .40 µmol/L was 
selected for the Phase I trial.20role for pazopanib in advanced renal cell carcinoma
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Pazopanib pharmacokinetics were evaluated in a 
Phase I dose-escalation study in human subjects with 
refractory solid tumors (discussed in more detail in the 
next section).20 Pazopanib is absorbed orally; however, 
with low oral bioavailability and solubility, there was 
limited absorption above doses of 800 mg. A median 
time to peak plasma concentration of 2 to 4 hours and 
a mean half-life of 30.9 hours after administration 
of an 800 mg dose was observed.20 Daily dosing at 
800 mg resulted in a mean AUC of 1,037 hr ⋅ µg/mL 
and Cmax of 58.1 µg/mL with no consistent increase 
in AUC or Cmax at pazopanib doses above 800 mg, 
although  the  highest  values  were  seen  in  patients 
receiving 2000 mg daily. Steady-state (Cmin) exposure 
plateaued at the 800 mg daily dose and there was no 
drug accumulation observed. Systemic exposure to 
pazopanib was increased with a high-fat or low-fat 
meal, resulting in an approximately 2-fold increase 
in AUC and Cmax, leading to the recommendation that 
pazopanib be administered at least 1 hour before or 
2 hours after a meal.21
Pazopanib  is  metabolized  mainly  by  the  cyto-
chrome  P450  enzyme  CYP3A4  in  the  liver,  with 
minor  contributions  from  CYP1A2  and  CYP2C8, 
and is highly protein-bound (.99.9%).19 As a result, 
plasma  pazopanib  concentrations  increase  when 
oral pazopanib is co-administered with a CYP3A4 
inhibitor. For example, concurrent administration of 
lapatinib, a substrate and weak inhibitor of CYP3A4, 
with pazopanib resulted in an approximately 50% to 
60% increase in mean pazopanib AUC(0–24) and Cmax 
compared  to  administration  of  pazopanib  alone.22 
Co-administration  of  pazopanib  with  paclitaxel, 
a  CYP3A4  and  CYP2C8  substrate,  resulted  in  a 
mean increase of 26% and 31% in the AUC and Cmax, 
respectively, of paclitaxel.23 A clinical pharmacology 
study demonstrated that pazopanib does not have a 
clinically  relevant  effect  on  the  pharmacokinetics 
of  caffeine  (CYP1A2  probe),  warfarin  (CYP2C9 
probe), or omeprazole (CYP2C19 probe), although 
it is weak inhibitor of CYP3A4 (midazolam probe) 
and  CYP2D6  (dextromethorphan  probe).24  Data 
from  a  Phase  I  pharmacokinetic  study  in  patients 
with varying degrees of liver dysfunction indicates 
that pazopanib clearance was decreased by 50% in 
patients with moderate hepatic impairment (defined 
as bilirubin 1.5 to 3 times the upper limit of normal) 
compared  with  those  with  normal  liver  function.25 
Therefore, the maximum pazopanib dose in patients 
with moderate hepatic impairment is recommended 
at 200 mg once daily.21 Pazopanib is excreted primar-
ily in the feces, with less than 4% excretion in the 
urine. Consequently, renal dysfunction is unlikely to 
change systemic exposure.21
Safety and Efficacy in Clinical Studies
phase I trial in refractory solid tumors
The first phase I study of pazopanib (VEG10003) was 
a multicenter, dose-finding trial incorporating phar-
macokinetic  and  pharmacodynamic  assessments.20 
Sixty-three patients with advanced solid tumors were 
enrolled, 43 in a dose-escalation cohort and 20 in a 
dose-expansion  cohort,  of  which  12  total  patients 
(19%) had renal cell carcinoma. In sequential dose-
escalation  cohorts,  subjects  received  50  mg  and 
100 mg three times weekly, 50 to 2000 mg once daily, 
and 300 to 400 mg twice daily. Pazopanib showed 
evidence of efficacy in various tumor types (Table 1), 
Table 1. phase I trial of pazopanib in patients with advanced 
cancer: selected baseline characteristics, disposition, and 
efficacy (n = 63).20
patients, n
Baseline characterististics
Mean age, years 56.5
primary disease site
  renal 12 (19%)
  Colorectal 11 (18%)
  Other gastrointestinal* 11 (18%)
  Breast 5 (8%)
  various other§ 24 (37%)
patient disposition
Dose-escalation cohort (n = 43)
  50–100 mg three times weekly 9
  50–2000 mg once daily† 34
Dose-expansion cohort (n = 20)
  800 mg once daily 11
  300–400 mg twice daily 9
Efficacy
partial response 3  
(2 renal cell   
carcinoma)
Stable disease $ 6 months 14  
(3 renal cell   
carcinoma)
notes: *pancreatic, liver, stomach;  §sarcoma, lung, prostate, angiosarcoma, 
endometrial,  fibrous  histiocytoma,  gastroinstestinalstromal  tumor,  head 
and neck, hepatobiliary, Hürthle cell, melanoma, mesothelioma, ovarian, 
carcinoma of unknown primary;  †3 patients were treated at the 800 mg 
daily dose level (recommended phase II dose).Harrison
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including renal cell carcinoma, and appeared to have 
a tolerable side effect profile.
Overall,  4  patients  experienced  dose-limiting 
  toxicities (DLTs): 2 patients at the 50 mg daily dose 
level (grade 3 gastrointestinal hemorrhage and grade 3 
extrapyramidal movement), 1 patient at the 800 mg 
daily dose level (grade 3 hypertension; subsequent 
grade 3 proteinuria), and 1 patient at the 2000 mg 
daily dose level (grade 3 fatigue). The most frequent 
drug-related adverse events (AEs) were hypertension 
(33%),  diarrhea (33%),  hair depigmentation (32%; 
sometimes associated with skin depigmentation), and 
nausea (32%). Most drug-related AEs were assessed 
as grade 1 or 2 by National Cancer Institute Common 
Toxicity Criteria (NCI CTC) version 2.0 and were 
reversible upon discontinuation of pazopanib.
The study defined grade 3 hypertension by stricter 
criteria than NCI CTC v2.0 (elevated blood pressure 
requiring therapy or more intensive treatment than pre-
viously), with the addition of a $15 mmHg rise from 
baseline in mean arterial blood pressure on at least 
3 separate occasions. Hypertension was the most fre-
quent grade 3 AE observed in the study. Twenty-nine 
percent of patients developed grade 3 hypertension 
by NCI CTC v2.0 and 62% by study-specific criteria. 
No hypertensive crises were observed and hyperten-
sion was manageable, with reversal upon pazopanib 
discontinuation.
Other  treatment-related  grade  3  AEs  included 
proteinuria,  diarrhea,  nausea,  increased  aspartate 
  aminotransferase,  extrapyramidal  disorder,  pelvic 
venous thrombosis, tumor hemorrhage, and deep venous 
thrombosis. One grade 4 AE (pulmonary embolism) 
and no treatment-related deaths were reported. Grade 3 
neutropenia was uncommon (3%) and although grade 3 
or 4 lymphopenia was observed in 14% of patients, 
no infections were reported. Treatment interruptions 
and/or dose reductions due to toxicity were required in 
10 patients (80% at doses between 800 and 2000 mg 
daily), with 2 patients permanently discontinued from 
pazopanib treatment for DLTs in cycle 1. Interestingly, 
though pazopanib demonstrated an overall similar tox-
icity  profile  to  other  multi-targeted  anti-angiogenic 
TKIs (eg, sunitinib and sorafenib), some notable dif-
ferences were observed. Hand-foot syndrome was not 
observed and asthenia (#2%), mouth ulceration and 
stomatitis (#2%), epistaxis (#3%), and drug-related 
rash (#6%) were uncommon.
The  maximum  tolerated  dose  (MTD)  dose  of 
pazopanib was not reached in this trial. Efficacy was 
seen, with 3 patients achieving a partial response (PR) 
and 14 patients with stable disease (SD) of $6 months’ 
duration  by  Response  Evaluation    Criteria  in  Solid 
Tumors (RECIST)
26 guidelines. Of the 12 patients with 
renal cell carcinoma, 2 patients had a   confirmed PR, 
4 patients had SD (3 with prolonged SD $ 6 months), 
4 patients had progressive disease, and 2 withdrew 
from the study due to toxicity. Notably, the renal cell 
carcinoma patients who achieved PR were naïve to 
prior antiangiogenic therapy.
Clinical activity in renal cell carcinoma patients in 
this study correlated with Cmin (steady-state) values 
of $15 µg/mL, in line with preclinical studies19 that 
showed optimal angiogenic inhibition at pazopanib 
concentrations $17.5 µg/mL (40 µmol/L). The 15 µg/mL 
threshold also correlated with the pharmacodynamic 
effect of hypertension. Overall, steady state exposure 
(Cmin) seemed to plateau at doses $ 800 mg daily, 
with 93% of patients at the 800 mg daily dose achiev-
ing  Cmin  $  15  µg/mL.  Because  of  these  reasons, 
coupled with the tolerable safety profile and pharma-
codynamic changes in tumor perfusion observed on 
DCE-MRI, the 800 mg daily dose was recommended 
for use in future studies.
phase II randomized discontinuation  
trial in mrCC
The  phase  II  study  (VEG102616)  in  patients  with 
  metastatic  renal  cell  carcinoma  was  originally 
designed  as  a  randomized  discontinuation  study 
(Fig.  1),  but  was  amended  to  an  open-label  study 
based on early evidence of efficacy at the planned 
interim analysis.27 Patients with locally recurrent or 
metastatic renal cell carcinoma with predominant clear 
cell   histology, Eastern Cooperative Oncology Group 
(ECOG) Performance Status (PS) #1, and measurable 
  disease by RECIST were enrolled. Treatment-naïve 
patients and those treated with one prior cytokine- or 
  bevacizumab-containing regimen were allowed. This 
study demonstrated that pazopanib is well-tolerated 
and has durable activity in this population.
Two-hundred  twenty-five  patients  were  enrolled 
over  one  year  (October  2005  to  September  2006) 
at 43 sites in 9 countries. After the first 60 patients 
had  completed  12  weeks  of  treatment,  a  planned 
interim analysis found the response rate to be 38%. role for pazopanib in advanced renal cell carcinoma
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  Therefore,  based  on  the  recommendation  of  an 
  Independent Data Monitoring Committee, random-
ization  ceased  and  all  patients  were  treated  on  an 
open-label  basis.  The  original  primary  endpoint 
of progressive disease (PD) rate at 16 weeks post-
randomization was revised to overall response rate 
(ORR) according to RECIST, with secondary end-
points of duration of response and progression-free 
survival (PFS). Approximately two-thirds of patients 
were treatment-naïve, over three-quarters were favor-
able or intermediate risk, and almost all had prior 
nephrectomy  (Table  2). The  ORR  was  35%  (95% 
CI: 28%–41%) by independent radiographic review 
with a median duration of response of 68 weeks. After 
statistical adjustment to account for patients randomly 
assigned to placebo, the median PFS attributable to 
pazopanib was 52 weeks (95% CI: 44–60 weeks).
Overall,  side  effects  were  tolerable  (Table  3). 
The  most  common  treatment-emergent  AEs  were 
diarrhea (63%), increased alanine aminotransferase 
(54%), increased aspartate aminotransferase (53%), 
fatigue  (46%),  hair  depigmentation  (43%),  nausea 
(42%), and hypertension (41%). The most common 
treatment-related  AEs  Grade  $  3  were  hyperten-
sion (9%), increased alanine aminotransferase (9%), 
increased  aspartate  aminotransferase  (7%),  diar-
rhea (4%), and fatigue (5%). Thirty-one percent of 
patients required dose reductions, although approxi-
mately  50%  of  these  patients  had    re-escalation. 
Key eligibility criteria:
• Metastatic RCC
• Clear cell-predominant
• Measurable by RECIST
• ECOG PS 0 or 1
• Treatment naïve or 
cytokine-pretreated*
Pazopanib
800 mg daily
CR/PR
SD
PD
Continue pazopanib
After
IA
N = 225
Before
IA
R
Continue pazopanib
Pazopanib
Placebo
n = 27
n = 28
12 weeks
*Prior bevacizumab-
containing regimens also 
allowed
Figure 1. Trial schema: Phase II randomized discontinuation study in patients with metastatic renal cell carcinoma (modified from Hutson et al).27
Abbreviation: IA, interim analysis.
Table 2. phase II trial of pazopanib in patients with meta-
static renal cell carcinoma: selected baseline characteris-
tics and evaluation of efficacy (n = 225).27
Baseline characterististics
Mean age 59.8 yrs
prior nephrectomy 91%
prior systemic therapy
  Cytokine alone 24%
  Cytokine + bevacizumab 4%
  Treatment naïve 69%
Median time since diagnosis 568 days
Sites of metastatic disease
  Lung 78%
  Lymph node 43%
  Bone 28%
  Liver 17%
MSKCC risk group
  Favorable 43%
  Intermediate 41%
Efficacy
response rate (95% CI) 34.7%  
(28.4 to 40.9)
Median duration of response (95% CI) 68.0 weeks  
(53.7 to Nr)
progression-free survival (95% CI) 51.7 weeks  
(43.9 to 60.3)
  Discontinuation  of  pazopanib  due  to  an  AE  was 
required  in  15%  of  patients.  Elevations  in  liver 
enzymes  (ie,  AST  or  ALT)  were  the  culprit  that 
led  to  discontinuation  in  4%  of  patients,  whereas 
  hypertension,  diarrhea,  and  fatigue/asthenia  rarely Harrison
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A retrospective analysis investigating the pharma-
cokinetics of pazopanib in relation to patient outcomes 
in this Phase II study was recently reported.28 Cmin(trough 
concentration) data was available for 205 patients at four 
weeks and 185 patients at 12 weeks out of the 225 total 
patients  enrolled. When  separated  into  quartiles  and 
stratified  by  PFS,  patients  with  a  plasma  pazopanib 
Cmin . 20.6 µg/mL at week 4 had a median PFS of 
49.4 weeks versus 20.3 weeks for patients in whom 
this plasma concentration of drug was not achieved. In 
addition, response rate (45% vs. 18%) and mean per-
cent tumor shrinkage (37.8% vs. 8.8%) were improved 
in the group who achieved this threshold at week 4. 
Almost 70% of patients assessed (143/205) were able to 
reach or exceed this concentration   threshold. Although 
retrospective, these data support both the initial dosage 
of 800 mg daily chosen for pazopanib in this population 
as well as a potential role for maintaining dose inten-
sity during treatment (ie, through optimizing supportive 
care) whenever possible.
phase III randomized trial in mrCC
A single phase III randomized, double blind, placebo 
controlled  trial  (Study  VEG105192)  of  pazopanib 
in metastatic renal cell carcinoma has been reported 
and was the basis for pazopanib’s FDA-approval in 
mRCC.10 Patients with clear cell or predominantly 
clear cell histology who had either received no prior 
therapy  or  who  had  progressed  on  only  one  prior 
cytokine-based  systemic  therapy  were  enrolled. 
Patients were randomized in a 2:1 ratio to receive 
pazopanib at 800 mg once daily or placebo (Fig. 2). 
Randomization  was  stratified  according  to  perfor-
mance status, prior nephrectomy, and prior   systemic 
Table  3.  phase  II  trial  of  pazopanib  in  patients  with 
  metastatic renal cell carcinoma: selected adverse events 
and laboratory abnormalities (n = 225).27
Any grade Grade 3 or 4
Adverse events (Ae)*
  Any AE 98% 53%
  Diarrhea 63% 4%
  Fatigue 46% 5%
  Hair depigmentation 43% 0%
  Nausea 42% ,1%
  Hypertension 41% 9%
  rash 16% ,1%
  Hand-foot syndrome 11% 2%
Laboratory abnormalities
  AST elevation 54% 7%
  ALT elevation 53% 9%
  Hyperbilirubinemia 28% ,1%
    Alkaline phosphatase  
elevation
27% 2%
  Lymphopenia 35% 1%
  Neutropenia 27% 4%
  Thrombocytopenia 26% 3%
  Anemia 26% 3%
note: *regardless of causality.
Key eligibility criteria:
• mRCC
• Clear cell component
• ECOG PS ≤ 1
• Prior therapy:
• Treatment naïve
• 1 Cytokine failure
Stratification:
• ECOG PS (0/1)
• Nephrectomy (Y/N)
• Prior therapy:
• Naïve (n = 233)
• Cytokine (n = 202)
Randomize
2:1
Pazopanib 800 mg daily
• Treatment naïve (n = 155)
• Cytokine failure (n = 135)
Matching placebo
• Treatment naïve (n = 78)
• Cytokine failure (n = 67)
Option to crossover to open-label 
pazopanib at progression (VEG107769)
n = 435
Figure 2. Trial schema: randomized phase III trial of pazopanib in locally advanced or metastatic renal cell carcinoma.10
led to   discontinuation. Notably, within the first few 
months  of  pazopanib  exposure,  isolated  asymp-
tomatic elevations of liver enzymes were observed. 
As  seen  in  the  Phase  I  study,  a  low  incidence  of 
grade $3 myelosuppression was observed, attributed 
to the pazopanib’s weak inhibitory activity for the 
Flt-3 receptor, and infrequent hand-foot syndrome and 
stomatitis/mucositis were seen. Two deaths considered 
to be treatment-related were observed (large bowel 
perforation in the setting of diverticulitis and dyspnea 
in the setting of   malignant pleural effusions).role for pazopanib in advanced renal cell carcinoma
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treatment  status.  Patients  who  progressed  on  the 
  placebo arm were allowed to enroll on an open label 
study of pazopanib (VEG107769). The primary end-
point was progression free survival with secondary 
endpoints  of  overall  survival,  confirmed  objective 
response rate, duration of response, safety, and health-
related quality of life (HRQoL).
Between April 2006 and April 2007, 435 patients 
were enrolled from 80 centers worldwide (Europe, 
South  America,  North  Africa,  Australia,  and 
New Zealand), with 290 patients randomly assigned 
to pazopanib and 145 to placebo. The arms were well 
balanced  with  regards  demographics  and  disease 
characteristics, including MSKCC risk category, prior 
nephrectomy, and histology (Table 4). The original 
design included only patients who had progressed on 
one prior cytokine-based systemic therapy, but was 
rapidly amended to include treatment-naïve patients. 
Therefore, of the 435 patients enrolled, 233 (54%) 
were treatment-naïve and 202 (46%) were cytokine-
pretreated.
Pazopanib significantly improved PFS compared 
to  placebo  (median  9.2  months  vs.  4.2  months; 
HR, 0.46; 95% CI, 0.34 to 0.62; P , 0.0001) in the 
overall study population. The improvement in PFS 
was  more  pronounced  in  the  treatment  naïve  sub-
population (median 11.1 vs. 2.8 months; HR, 0.40; 
95%  CI:  0.27  to  0.60;  P  ,  0.0001),  although  the 
cytokine-pretreated subpopulation benefited as well 
(median 7.4 vs. 4.2 months, HR, 0.54; 95% CI, 0.35 
to 0.84; P , 0.001). Predefined subgroup analyses 
supported  the  improvement  in  PFS  for  pazopanib 
treated  patients  in  all  categories  (regardless  of 
MSKCC risk group, systemic treatment status, gen-
der, age, or ECOG PS). The objective response rate 
for the overall study population was 30% (95% CI, 
25.1% to 35.6%), with a median duration of response 
of 58.7 weeks. 
Interim analysis of overall survival (OS) based on 61% 
of the required death events did not meet either superiority 
or futility.10 However, final OS results have now been 
reported, with a median OS of 22.9 versus 20.5 months 
in the pazopanib and placebo arms, respectively (HR, 
0.91; 95% CI, 0.71 to 1.16; P = 0.224).29 The early timing, 
high rate, and prolonged duration of crossover from the 
placebo arm to open-label pazopanib is likely to have 
confounded the OS analysis. Ultimately, 54% of placebo 
arm patients crossed over to open-label pazopanib and 
they  remained  on  pazopanib  treatment  longer  than 
patients originally randomized to the blinded pazopanib 
arm  (9.4  vs.  7.4  months,  respectively).  A  post-hoc 
inverse probability of censoring weighted (IPCW) anal-
ysis, designed to adjust for crossover, showed a 50% 
reduction in the risk of death with pazopanib treatment 
compared  with  placebo  (HR,  0.50;  95%  CI,  0.32  to 
0.76; P = 0.002). In summary, pazopanib appeared to 
have beneficial clinical activity in the study   population. 
The  efficacy  of  pazopanib  compares  favorably 
with  other  approved  first-line  regimens  for  mRCC 
(Table 5).
Overall,  pazopanib  was  also  well  tolerated  in 
this population of mRCC patients (Table 6), as sug-
gested  by  the  Phase  I  and  Phase  II  studies.  Most 
AEs were grade # 2 and the most common AEs in 
the pazopanib arm were diarrhea (52%), hyperten-
sion (40%), hair color changes (38%), nausea (26%), 
anorexia (22%), and vomiting (21%). The most com-
mon grade 3 or 4 AEs in the pazopanib arm were 
hypertension (4%) and diarrhea (4%). Of note, the 
incidence of arterial thrombotic events was 3% of 
pazopanib-treated patients compared with none in the 
placebo arm. Hemorrhagic events (all grades) were 
observed in 13% and 5% of patients in the pazopanib 
and  placebo  arms,  respectively.  Most  laboratory 
abnormalities were grade # 2, most commonly ALT 
elevation  (53%)  and  AST  elevation  (53%)  in  the 
pazopanib arm. Of note, ALT elevation $3 times the 
Table  4.  Selected  patient  demographics  and  disease 
characteristics: randomized phase III trial of pazopanib in 
mrCC.10
Baseline characterististics pazopanib  
(n = 290)
placebo  
(n = 145)
Median age, years 59 59
prior nephrectomy 89% 88%
prior systemic therapy
  Cytokine pretreated 47% 46%
  Treatment naïve 53% 54%
Median time since  
diagnosis, months
15.7 13.8
Sites of metastatic disease
  Lung 74% 73%
  Lymph node 54% 59%
  Bone 28% 26%
  Liver 26% 22%
MSKCC risk group
  Favorable 39% 39%
  Intermediate 55% 53%Harrison
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Table 5. response rate (rECIST), progression-free survival, and overall survival in 1st line phase III trials in patients with 
good-intermediate risk metastatic renal cell carcinoma.
Regimen Trial cR pR sD Median  
response  
duration
ORR pFs  
(P-value)
Os  
(P-value)
pazopanib* pazopanib vs. placebo10,29 ,1%* 30%* 38%* 13.5 mos* 32% 11.1 mos  
(,0.0001)
22.9 mos*   
(0.224)
Sunitinib Sunitinib vs. IFN-α9,47 3% 44% 40% 11.0 mos 47% 11.0 mos  
(,0.001)
26.4 mos  
(0.051)
Bevacizumab +  
IFN-α
AvOrEN (Bev. + IFN-α vs.  
pbo + IFN-α)13,48
1% 30% 46% 13.5 mos 31% 10.2 mos  
(,0.0001)
23.3 mos  
(0.1291)
CALGB 90206  
(Bev. + IFN-α vs. IFN-α)14
Nr 25.5% Nr 11.9 mos 25.5% 8.5 mos  
(,0.0001)
18.3 mos  
(0.069)
notes: *Starred parameters are for the entire study population (cytokine-pretreated patients and treatment-naïve patients) since these values were not 
reported separately for the treatment-naïve subgroup.
Abbreviations: rECIST, response Evaluation Criteria in Solid Tumors; Cr, complete response; pr, partial response; Orr, overall response rate; SD, 
stable disease; IFN-α, interferon-alfa; Mos, months; Nr, not reported; pbo, placebo.
Table 6. Selected adverse events in 1st line phase III trials in patients with good-intermediate risk metastatic renal cell 
carcinoma.
Adverse event or laboratory  
abnormality
pazopanib (%)10,21  
(n = 290)
sunitinib (%)9,49  
(n = 375)
Bevacizumab +  
IFn-α (%)50,51  
(n = 337)
All Grade 3 or 4 All Grade 3 or 4 All Grade 3 or 4
Diarrhea 52 4 53 5 20 2
Hypertension 40 4 24 8 26 3
Fatigue 19 2 51 7 33 12
Asthenia 14 3 17 4 32 10
Hand-foot syndrome 6 ,1 20 5 NS NS
Mucositis/stomatitis ,10 ,1 45* 3* NS NS
Arterial thrombotic events NS 3 NS NS 1 1
venous thromboembolic events NS NS NS 2 3 2
Hemorrhagic events 13 NS 37 4 33 3
Cardiac dysfunction† ,1 NS 10 2 ,1‡ ,1‡
ALT increase 53 12 52 2 NS NS
AST increase 53 8 46 3 NS NS
Total bilirubin increase 36 3 19 1 NS NS
Hypothyroidism 7 ,1 16 NS NS NS
proteinuria 9 ,1 NS NS 18 7
Anemia NS NS 71 4 10 3
Thrombocytopenia 32 1 65 8 6 2
Neutropenia 34 1 72 12 7 4
Leukopenia 37 0 78 5 NS NS
Discontinuation due to AE(s) 14 8 28
notes: *Reported categories of “stomatitis” and “mucosal inflammation” added together;  †includes decreased ejection fraction and congestive heart 
failure. ‡Congestive heart failure only; decreased ejection fraction not specified.
Abbreviation: NS, not specified.
upper limit of normal occurred in 18% of patients and 
recovered to #grade 1 upon dose modification, inter-
ruption, or discontinuation in 87% of these patients. 
In the pazopanib arm, 1% of patients (n = 4) had 
fatal AEs assessed as drug-related (1 patient each): 
  abnormal  hepatic  function  and  rectal  hemorrhage, 
abnormal  hepatic  function  with  extensive  infiltra-
tion of metastatic disease, peritonitis/bowel perfora-
tion at a site of RCC metastasis, and ischemic stroke. 
Again, key class side effects of anti-angiogenic TKIs role for pazopanib in advanced renal cell carcinoma
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were observed with low   frequency in this trial (10% 
any grade and .1% grade 3 or 4): hand-foot syn-
drome,  mucositis/  stomatitis,  hypothyroidism,  and 
  proteinuria. A low rate (#1%) of grade 3 or 4 cytope-
nias was observed, attributed to pazopanib’s lack of 
potency for the fms-related tyrosine kinase (Flt-3). 
With a 30% increase in the cumulative exposure to 
pazopanib  since  the  published  report,  safety  data 
from this Phase III trial have recently been updated.30 
No new safety signals were identified: there were no 
significant changes in the type, frequency, or severity 
of AEs and no differences in grade 3, 4, or 5 AEs.
Several interesting toxicity-related analyses of this 
trial have been published or reported in abstract form. 
A genetic analysis performed by Xu et al attempted 
to identify genetic markers that predict for risk of 
ALT  and/or  bilirubin  elevation  in  patients  treated 
with  pazopanib  in  the  phase  II  and  III  studies.31 
  Interestingly, the UGT1A1 TA repeat polymorphism 
was strongly associated with maximum on-treatment 
bilirubin concentration and bilirubin increase from 
baseline,  while  none  of  the  polymorphisms  tested 
was associated with elevation of ALT. Therefore, it 
may important to consider that isolated elevations of 
total bilirubin may not indicate pazopanib-induced 
hepatotoxicity and could be benign manifestations of 
Gilbert’s syndrome. An analysis of the 578 patients 
enrolled  on  the  Phase  II,  Phase  III,  and  Phase  III 
extension trials found an overall incidence of hypo-
thyroidism  of  3%  and  hyperthyroidism  of  1%.32 
The low rate of hypothyroidism is hypothesized to 
partially explain the low rates of fatigue (19%) and 
asthenia (14%) observed in the Phase III trial.
Another study, recently presented in abstract form, 
examined demographic, pharmacokinetic (PK), and 
pharmacogenetic  (PGx)  factors  that  contribute  to 
pazopanib-related hand-foot syndrome (HFS) using 
samples from the Phase II and III trials in mRCC 
patients.33 While the overall incidence of HFS was low 
(7.7%) in the overall population, Asian race (incidence 
of 30% compared with 4% for Caucasians) and week 
4 Cmin plasma pazopanib concentration appeared to be 
predictors of HFS. Finally, the relationship between 
week 4 plasma pazopanib concentration (Cmin) and 
clinically important AEs in the first 12 weeks of treat-
ment was explored using data from 205 patients in 
the Phase II trial.34 The incidence of diarrhea, hair 
color change, ALT increase, HFS, and stomatitis AEs 
was concentration-dependent, whereas the incidence 
of other common AEs (ie, nausea, vomiting, fatigue, 
dysgeusia, and rash) was not. It is hypothesized that 
a dose-reduction strategy might be more appropri-
ate for concentration-dependent AEs than for other 
AEs. Although retrospective, these analyses provide 
important additional clues about clinically meaning-
ful pazopanib-related toxicities.
Emerging data: TKI refractory patients,  
pazopanib combinations, and biomarkers
There was previously no data for pazopanib in TKI 
failure; however, two studies suggesting pazopanib’s 
efficacy in this setting have recently been presented in 
abstract form. Matrana et al presented a retrospective 
review of MD Anderson’s experience with pazopanib 
in  88  consecutive  mRCC  patients  who  experienced 
progression  on  other  targeted  agents.35  The  median 
number of prior targeted agents was 2 (range, 1 to 5), 
including 78% of patients having progressed on suni-
tinib, 51% on everolimus, 40% on sorafenib, 26% on 
bevacizumab, and 20% on temsirolimus. In this refrac-
tory population, the partial response rate was 25% by 
treating physician assessment, providing evidence for 
clinically meaningful activity. Reeves et al presented 
a  single-institution  prospective  Phase  II  trial  in  44   
patients who had progressed on prior anti-angiogenic 
agents. Thirty-two patients (72%) had progressed on 
prior sunitinib (SU) and 12 patients (28%) had progressed 
on prior bevacizumab (bev). The overall response rate 
by RECIST was 20% (SU: 16%; bev: 33%), with a 
77% disease control rate (CR + PR + SD) and a median 
PFS of 9.23 months (SU: 12 months; bev: 8 months). 
Pazopanib was also well tolerated, with toxicities simi-
lar to those previously reported. These 2 studies provide 
preliminary (level 2) evidence for pazopanib’s efficacy 
in targeted therapy-refractory patients.
A phase I study investigating “vertical   inhibition” 
of  the  VEGFR  and  mTOR  pathways  with  dose-
  escalation  of  combination  pazopanib  plus  temsi-
rolimus in patients with solid tumors (emphasis on 
mRCC) was recently reported.36 Although there was 
some  evidence  of  activity,  dose  de-escalation  was 
required due to DLTs at the first dose level and the 
investigators determined that this combination is not 
feasible. This is in concordance with prior studies 
of  different  anti-VEGF  and  -mTOR  combinations, 
which showed unacceptable toxicity.Harrison
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Finally, recent studies have attempted to identify 
biomarkers predictive of treatment benefit. Xu and 
colleagues  reported  2  studies  evaluating  germ-line 
single  nucleotide  polymorphisms  (SNPs)  selected 
based on the following criteria: involvement in angio-
genesis or the metabolism, disposition, or mode of 
action  of  pazopanib;  and  a  previously  established 
functional  or  biologically  relevant  consequence  of 
the  genetic  polymorphism.37  Twenty-seven  func-
tional polymorphisms within 13 genes were evalu-
ated  and  associated  with  progression-free  survival 
(PFS) and response rate (RR) in 397 patients with 
mRCC receiving pazopanib on phase II, phase III, 
and phase III extension studies.37 Similarly, the same 
functional polymorphisms were correlated with over-
all  survival  (OS)  in  214  pazopanib-treated  mRCC 
patients from the phase III and its extension   studies. 
Polymorphisms  in  IL8,  HIF1A,  NR1lA,  and 
VEGFA  showed  nominally  significant  associations 
(P # 0.05) with PFS and RR when compared with 
the wild-type genotypes. In addition, polymorphisms 
in IL8, FGFR2, NR1I2 and ABCB1 showed nomi-
nal associations with OS (P # 0.05) and were shown 
to  be  independent  predictors  of  OS  on  multivari-
ate analysis. These findings are important, because 
these germ-line polymorphisms in angiogenesis and 
exposure-related genes might be used to predict those 
mRCC patients who will benefit from pazopanib and, 
more importantly, spare those patients who will not 
benefit from potential pazopanib toxicities. However, 
more work will need to be done to prospectively vali-
date this approach.
Role for pazopanib in mRcc
With the dramatic advances in treatment of mRCC in 
the last decade, several unanswered questions come 
to the forefront: What is the best first-line systemic 
therapy for mRCC? and, What is the best systemic 
therapy  for  cytokine-  and  VEGFR  TKI-refractory 
patients? An evidence-based approach to upfront and 
subsequent  therapy  based  on  the  inclusion  criteria 
in phase III trials and other patient characteristics is 
  necessary. The National Comprehensive Cancer Net-
work (NCCN) has developed categories of evidence 
and consensus: Category 1 evidence is based on high-
level evidence (ie, randomized controlled trials) and 
consensus, Category 2 evidence is based on lower level 
evidence where there may be minor   disagreement, 
and Category 3 evidence is based on any level of 
  evidence with major disagreement.38 Important fac-
tors to consider include MSKCC risk group,39 number 
and type of prior therapies, histologic subtype (clear 
cell or clear-cell predominant versus non-clear cell), 
and patient-specific characteristics (ie, comorbidities 
in relation to agent-specific toxicities and financial 
considerations). Pazopanib’s role will be discussed in 
three settings: first-line (treatment-naïve), cytokine-
refractory  (second-line),  and  anti-VEGF-refractory 
(second-line), and beyond.
Treatment-naïve patients (1st line)
There is Level 1 evidence for pazopanib use in the 
first-line setting for patients with favorable or interme-
diate risk, predominantly clear cell renal carcinoma. 
Other equally appropriate agents for treatment-  naïve 
patients with favorable or intermediate risk and pre-
dominant  clear  cell  histology  include  sunitinib,  or 
bevacizumab plus interferon-α (Fig. 3). High dose 
IL-2 may also be reasonable in a selected group of 
patients. Patients’ symptoms and co-morbidities that 
might  be  exacerbated  by  agent-  specific  toxicities 
should be considered before initiating treatment. For 
example, in the absence of data showing superiority 
of any of the 3 regimens (Table 5), pazopanib might 
be chosen in a patient with moderate fatigue at base-
line (see Table 6). In poor risk and/or or non-clear 
cell histology patients, there is Level 1 evidence for 
a survival advantage with temsirolimus, an intrave-
nously administered inhibitor of the mammalian tar-
get of rapamycin (mTOR) pathway, when compared 
with interferon-α alone in the first line setting.
Patient  preference  amongst  the  evidence-based 
first-line treatments (ie, pazopanib, sunitinib, or beva-
cizumab + IFN-α) for favorable or intermediate risk 
metastatic renal cell carcinoma is unknown. Although 
these questions have been examined in retrospective 
studies, they may be subject to bias. Discussion of 
both side effects and the convenience of oral therapy, 
among other factors, will be critical in the decision-
making process for patients with mRCC. The lack 
of head-to-head comparison studies limits definitive 
conclusions; however, pazopanib may exhibit several 
key differences compared with sunitinib that could 
lead to patient preference for pazopanib (Table 6). 
The toxicity profiles of pazopanib and sunitinib in the 
Phase III trials in mRCC would suggest that the lower role for pazopanib in advanced renal cell carcinoma
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Advanced RCC:
• Favorable-intermediate risk*
• ≥Clear cell component
Sunitinib
Pazopanib
Bevacizumab
+ IFN-α
*MSKCC risk factors:
1. Low Karnofsky PS (<80%)
2. High LDH (>1.5xULN)
3. Low hemoglobin (<LLN)
4. High corrected calcium (>10 mg/dL)
5. Absence of prior nephrectomy
Favorable: 0 risk factors
Intermediate: 1–2 risk factors
Poor: ≥3 risk factors
Figure 3. Evidence-based treatment algorithm for treatment-naïve mrCC. Note that high dose IL-2 may be considered in carefully selected patients.
incidence of fatigue, hand-foot   syndrome, mucosi-
tis/stomatitis, hypothyroidism, and   hematologic lab 
abnormalities might favor pazopanib. On the other 
hand,  patients  with  poorly  controlled/difficult  to 
treat hypertension or baseline liver dysfunction may 
well have greater difficulty with pazopanib. Finally, 
patients who prefer an intravenous regimen over an 
oral  regimen  (eg,  for  financial  reasons)  may  pre-
fer bevacizumab + IFN-α. Some of these questions 
regarding patient preferences and differential toxic-
ity profiles will hopefully be answered more defini-
tively in the prospective PISCES study, comparing 
pazopanib and sunitinib, discussed below. Of course, 
toxicity and other preference considerations may be 
moot if non-inferiority of pazopanib with sunitinib 
cannot  be  demonstrated  in  the  COMPARZ  study, 
also discussed below.
Cytokine-refractory patients (2nd line)
The population of cytokine-refractory patients is dra-
matically shrinking now that six targeted therapy regi-
mens for advanced renal cell carcinoma are approved. 
Therefore,  the  question  of  how  to  use  these  novel 
agents in cytokine-refractory disease is currently less 
pressing.  However,  randomized  controlled  studies 
of  pazopanib,10  axitinib  (abstract  form  only),40  and 
sorafenib8,41 provide category 1 evidence supporting 
their use in this population (Table 7). Of note, axitinib 
Table 7. response rate (rECIST), progression-free survival, and overall survival in phase II/III trials in cytokine-  refractory 
patients with metastatic renal cell carcinoma.
Regimen Trial n, patients ORR pFs  
(P-value)
Os  
(P-value)
pazopanib pazopanib vs. placebo  
(phase III)10
290 29% 7.4 mos  
(,0.0001)*
Nr
Axitinib Axitinib vs. sorafenib  
(phase III)40
251 Nr 12.1 mos  
(,0.0001)†
Nr
Sorafenib Sorafenib vs. placebo  
(phase III)8,41
451 2% 5.5 mos  
(,0.01)
17.8 mos   
(0.146)
Sunitinib Single-arm  
phase II42,43
105 34% 8.3 mos Nr
notes: *result from cytokine-pretreated subpopulation; †result from subgroup analysis. P-value is for one-sided log rank test stratified by performance 
status.Harrison
360  Clinical Medicine Insights: Oncology 2011:5
mRCC:
Predominant
clear cell 
histology
Cytokines
Pazopanib
Sunitinib
First line Second line
P
r
o
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r
e
s
s
i
o
n
(Axitinib*)
Sorafenib
Figure  4.  Evidence-based  treatment  algorithm  for  cytokine-refractory 
mrCC. 
note: *As of this writing axitinib is not FDA-approved for this use, but 
would be reasonable based on available evidence.
Table 8. response rate (rECIST), progression-free survival, and overall survival in selected phase II/III trials in vEGFr 
TKI-refractory patients with metastatic renal cell carcinoma.
Regimen Trial setting n, patients ORR pFs  
(P-value)
Os  
(P-value)
Everolimus Everolimus vs. placebo  
(phase III)12,44
45%—prior sunitinib; 29%—
prior sorafenib; 26%—both*
277 1.8% 4.9 mos  
(P , 0.001)
14.8 mos  
(P = 0.162)
Axitinib Axitinib vs. sorafenib  
(phase III)40
Sunitinib subgroup analysis 389 Nr 4.8 mos  
(0.011)
Nr
pazopanib Single-arm  
phase II52
72%—prior sunitinib; 28%—
prior bevacizumab
44 20% 9.3 mos  
(NA)
Nr
note: *65% of patients also had prior immunotherapy and 13% had prior chemotherapy, meaning this population appeared to be more heavily pre-treated 
than in the phase III trial of axitinib (AxIS).
Abbreviations: Nr, not reported; NA, not applicable.
was the only drug tested against an active comparator 
(sorafenib); therefore, axitinib may be preferred and 
sorafenib may no longer be reasonable in this popu-
lation. The publication of the axitinib data in a peer-
reviewed journal is eagerly awaited. In addition, there 
is strong evidence for the activity of sunitinib in this 
population from phase II studies42,43 and extrapolation 
from sunitinib’s activity in the front-line Phase III trial. 
Because the use of VEGFR signaling pathway inhibi-
tors for first line treatment is now standard of care 
except in select patients, the population of cytokine-re-
fractory patients in clinical practice is likely to dwindle 
in coming years. In summary, pazopanib is a reason-
able treatment option in cytokine-refractory patients, 
although it should be noted that axitinib, while not yet 
FDA-approved, has recently demonstrated improved 
PFS versus an active comparator (Fig. 4).
Anti-vEGF pretreated patients  
(2nd line and beyond)
Two  agents  have  Level  1  evidence  for  efficacy 
in  VEGFR  TKI-treated  patients:  everolimus  and 
axitinib  (Table  8).  Everolimus,  an  mTOR    inhibitor, 
improved  progression-free  survival  (4.9  vs. 
1.9  months;  HR,  0.33;  P  ,  0.001)  versus  placebo 
in patients who had progressed on sunitinib (46%), 
sorafenib (28%), or both (26%).12,44 Of note, two-thirds 
of patients had also been treated with immunotherapy 
(ie,  IFN-α  or  high-dose  IL-2).  More  recently  axi-
tinib, a   second-generation inhibitor of VEGFR-1, -2, 
and -3,   demonstrated improved progression-free sur-
vival (6.7 vs. 4.7 months; HR, 0.665; P , 0.0001) in a 
population of mainly sunitinib- (54%) and cytokine-
pretreated (35%) patients.40 Should axitinib be FDA-
approved,  either  everolimus  or  axitinib  would  be 
reasonable in this population, with no data to suggest 
one’s superiority over the other. In comparison, there 
is limited evidence for pazopanib’s efficacy in VEGFR 
TKI- and bevacizumab-pretreated patients, with one 
prospective phase II study and one single-institution 
retrospective review suggesting efficacy (see above). 
So, while pazopanib may be reasonable in further lines 
of  therapy,  everolimus  remains  the  evidence-based 
standard of care for this population, at least while axi-
tinib remains yet to be FDA-approved (Fig. 5). Clinical 
trials of novel agents should also be considered.
selected Ongoing Trials
Further  studies  that  will  help  define  the  role  of 
pazopanib as monotherapy in the 1st line (treatment 
naïve) setting include two ongoing phase III trials: 
(1) COMPARZ (Pazopanib Versus Sunitinib in the 
Treatment of Subjects With Locally Advanced and/or 
Metastatic Renal Cell Carcinoma)45 and (2) PISCES 
(Patient  Preference  Study  of  Pazopanib  Versus role for pazopanib in advanced renal cell carcinoma
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mRCC:
Predominant
clear cell 
histology
VEGFR TKI
1. Everolimus 
(or axitinib†)
2.  Clinical trial
First line Second line
(in order of preference)
P
r
o
g
r
e
s
s
i
o
n
3.  Different anti-
VEGF agent§
Figure 5. Evidence-based treatment algorithm for vEGFr TKI-  refractory 
mrCC. 
notes:  †As  of  this  writing  axitinib  is  not  FDA-approved  for  this  use, 
but would be reasonable based on available evidence; §ie, pazopanib, 
sunitinib, bevacizumab, or sorafenib.
Table 9. Select ongoing/planned trials that may clarify the role of pazopanib in renal cell carcinoma.
setting phase n, planned Description ncT#
non-metastatic
Neoadjuvant II 30 pazopanib before surgery for  
localized rCC
NCT0115852153
II 40 Neoadjuvant pazopanib for  
localized rCC
NCT0136111354
Adjuvant III 1500 Adjuvant pazopanib for localized  
rCC (pROTecT)
NCT0123596255
Advanced/metastatic
Treatment-naïve III 876 Pazopanib vs. sunitinib efficacy  
(cOMpARZ)
NCT0072094156
III 161 pazopanib vs. sunitinib patient  
preference (pIsces)
NCT0106431057
II (randomized) 160 pazopanib vs. sunitinib in Asian  
patients
NCT0114782258
II (randomized) 90 pazopanib vs. temsirolimus in  
poor-risk patients*
NCT0139218359
vEGFr TKI-refractory II 28 pazopanib after 1 or 2 systemic  
therapies, with 1 vEGFr TKI  
required
NCT0115709160
Combinations: anti-vEGF I 36 Dose-escalation of pazopanib  
and bevacizumab (pARAsOL)
NCT0120203261
Combinations: mTOr  
inhibition
I 44 Dose-escalation of pazopanib  
and everolimus
NCT0118432662
Sequencing of monotherapy II (randomized) 240 Sequential assessment of 2 
monotherapies (sTART): 
1. pazopanib → bevacizumab 
2. pazopanib → everolimus 
3. Everolimus → pazopanib 
4. Bevacizumab → pazopanib 
5. Everolimus → bevacizumab 
6. Bevacizumab → everolimus
NCT0121793163
II (randomized) 100 rotation between everolimus and 
pazopanib every 2 months vs. 
pazopanib until progression  
followed by everolimus (ROpeTAR)
NCT0140800464
I (pharmaco- 
dynamic)
12 3 infusions of bevacizumab  
q2 weeks followed by pazopanib  
on various schedules
NCT0099212165
note: *prior cytokines or vaccines allowed but not prior systemic targeted therapies.
  Sunitinib in Advanced or Metastatic Kidney Cancer).46 
The COMPARZ trial (VEG108844) is designed to 
test pazopanib versus sunitinib (Sutent®; Pfizer, Inc.) 
in locally advanced and/or metastatic RCC patients 
who  have  had  no  prior  treatment.  Approximately 
876 patients with treatment naïve metastatic clear cell 
RCC will be included, with a primary endpoint powered 
to show non-inferiority of progression-free   survival. 
Importantly, this study will allow head-to-head com-
parison  of  the  tolerability  of  pazopanib  compared 
with sunitinib. The PISCES trial will address patient Harrison
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preferences between pazopanib and sunitinib. This 
trial is a randomized,   double-blind, crossover study of 
pazopanib versus sunitinib in patients with metastatic 
RCC who have received no prior systemic therapy. 
Patients will be randomized to sunitinib for 10 weeks 
followed by pazopanib for 10 weeks (2 week wash-
out period between agents), or the inverse sequence. 
Approximately  160  patients  are  planned,  with  the 
primary endpoint based on a patient preference ques-
tionnaire at 22 weeks. As of this writing, results from 
both trials are expected within the next year. Other 
pazopanib studies of interest include those in the neo-
adjuvant,  adjuvant,  first-line  comparative,  VEGFR 
TKI-refractory, combination, and sequencing settings 
(Table 9).
conclusions
Although approved more recently than other VEGFR 
TKIs, pazopanib is an important option in the arma-
mentarium of treatment options of metastatic renal 
cell  carcinoma.  There  is  data  from  randomized 
Phase III trials supporting pazopanib’s efficacy and 
safety  in  treatment-naïve  and  cytokine-refractory 
patients  with  mRCC.  Due  to  its  low  incidence  of 
fatigue,  mucositis/stomatitis,  hand-foot  syndrome, 
and hematologic toxicities compared with sunitinib, 
pazopanib may be a unique therapeutic option. Data 
from the COMPARZ and PISCES trials are awaited 
to  confirm  pazopanib’s  comparable  efficacy  and 
improved toxicity compared with sunitinib, in order 
to more fully define pazopanib’s role in the treatment 
of mRCC.
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